
Vanguard is moving into private equity, reflecting strong demand for the asset class and raising the possibility of rising fee pressure in the most profitable sector of the global investment industry.
Pennsylvania-based Vanguard — the world’s second biggest investment group, with more than $6tn in assets under management — has struck a strategic partnership with HarbourVest, a $68bn private market specialist, to provide qualified investors with access to private equity.
Vanguard’s late founder Jack Bogle famously detested high-fee funds. Its move into a market dominated by US private equity giants such as Apollo Global Management, Blackstone Group and Carlyle Group marks a departure from the investment group’s traditional approach.
Vanguard plans to launch a private equity fund each year with HarbourVest, which will use the money for buyouts and also invest it in funds run by other private equity firms, said Fran Kinniry, head of private investments at Vanguard. However these are unlikely to include the industry’s largest funds run by the likes of KKR, Carlyle and Blackstone.
“HarbourVest will invest directly in deals but will also partner with general partners in certain areas,” said Mr Kinniry, who declined to comment on fees. ”Access to the best managers in the space is critical. HarborVest has been getting top access and the performance continues to be strong.”
Full Content: Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google Urges Texas Judge to Disregard Virginia Antitrust Ruling
May 14, 2025 by
CPI
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Rumble Adds David Boies to Legal Team in $2 Billion Antitrust Battle with Google
May 14, 2025 by
CPI
China Summons Delivery Giants Over Unfair Competition Concerns
May 13, 2025 by
CPI
Judge Orders Sanctions Against Missouri for Noncompliance in Price-Fixing Probe
May 13, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas